ATE555131T1 - Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten - Google Patents

Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten

Info

Publication number
ATE555131T1
ATE555131T1 AT09702831T AT09702831T ATE555131T1 AT E555131 T1 ATE555131 T1 AT E555131T1 AT 09702831 T AT09702831 T AT 09702831T AT 09702831 T AT09702831 T AT 09702831T AT E555131 T1 ATE555131 T1 AT E555131T1
Authority
AT
Austria
Prior art keywords
depositive
diseases
treating bone
csf antagonist
csf
Prior art date
Application number
AT09702831T
Other languages
English (en)
Inventor
Christopher R Bebbington
Geoffrey T Yarranton
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40673999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE555131(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE555131T1 publication Critical patent/ATE555131T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT09702831T 2008-01-15 2009-01-15 Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten ATE555131T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2121808P 2008-01-15 2008-01-15
PCT/US2009/031126 WO2009091905A1 (en) 2008-01-15 2009-01-15 Methods of treating bone-loss disorders using a gm-csf antagonist

Publications (1)

Publication Number Publication Date
ATE555131T1 true ATE555131T1 (de) 2012-05-15

Family

ID=40673999

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09702831T ATE555131T1 (de) 2008-01-15 2009-01-15 Verfahren zur behandlung von erkrankungen mit knochenabbau unter verwendung eines gm-csf- antagonisten

Country Status (10)

Country Link
US (2) US20090181020A1 (de)
EP (1) EP2245062B1 (de)
JP (1) JP2011510015A (de)
CN (1) CN101932603A (de)
AT (1) ATE555131T1 (de)
AU (1) AU2009206082A1 (de)
BR (1) BRPI0907220A2 (de)
CA (1) CA2711763A1 (de)
EA (1) EA201001162A1 (de)
WO (1) WO2009091905A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
AU2008287426B2 (en) * 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
SI3312195T1 (sl) * 2013-03-20 2020-02-28 Genzyme Corporation Postopki zdravljenja osteogeneze imperfecta
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
CN107655871A (zh) * 2017-09-12 2018-02-02 重庆医科大学 一种阿仑膦酸钠的高灵敏宽检测范围荧光检测新方法
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
CN117126277B (zh) * 2023-10-26 2024-01-23 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0673389A1 (de) * 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antikörper gegen den gm-csf rezeptor und dessen verwendung
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
EP1051432B1 (de) 1998-12-08 2007-01-24 Biovation Limited Verfahren zur verminderung der immunogenität von proteinen
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法

Also Published As

Publication number Publication date
JP2011510015A (ja) 2011-03-31
US20120009191A1 (en) 2012-01-12
AU2009206082A1 (en) 2009-07-23
BRPI0907220A2 (pt) 2019-02-26
EP2245062B1 (de) 2012-04-25
CN101932603A (zh) 2010-12-29
CA2711763A1 (en) 2009-07-23
WO2009091905A1 (en) 2009-07-23
EA201001162A1 (ru) 2010-12-30
EP2245062A1 (de) 2010-11-03
US20090181020A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
EA201691260A1 (ru) ВАРИАНТЫ, ПРОИСХОДЯЩИЕ ИЗ ActRIIB, И ИХ ПРИМЕНЕНИЕ
EA201592238A1 (ru) Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
EA201070822A1 (ru) Доставка антител посредством модульного домена распознавания
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
EA201991704A2 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2